Abstract
Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Current Drug Delivery
Title: Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Volume: 8 Issue: 1
Author(s): Hong Song and George Sgouros
Affiliation:
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Abstract: Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Export Options
About this article
Cite this article as:
Song Hong and Sgouros George, Radioimmunotherapy of Solid Tumors: Searching for the Right Target, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663651
DOI https://dx.doi.org/10.2174/156720111793663651 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Synthetic and Application Perspectives of Azapodophyllotoxins: Alternative Scaffolds of Podophyllotoxin
Current Medicinal Chemistry Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Hodgkin Lymphoma in HIV Positive Patients
Current HIV Research Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Carbon Monoxide in Acute Lung Injury
Current Pharmaceutical Biotechnology MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs
Clinical Cancer Drugs The Inhibition of Cell Proliferation Using Silencing of N-Cadherin Gene by siRNA Process in Human Melanoma Cell Lines
Current Medicinal Chemistry Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Helicobacter suis Infection in Mouse Induced not Only Gastric, but Hepatic and Pulmonary MALT Lymphoma: Relation to Substance P
Current Pharmaceutical Design Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology